First oncolytic virus approved for melanoma immunotherapy

Oncoimmunology. 2015 Dec 8;5(1):e1115641. doi: 10.1080/2162402X.2015.1115641. eCollection 2016.


On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

Keywords: Granulocyte macrophage colony-stimulating factor; Imlygic®; OPTiM; OncoVEXGM-CSF; T-vec; talimogene laherparepvec.

Publication types

  • Research Support, Non-U.S. Gov't